Newsletter September 2024
Advancing Tumor Resistance Models at EPO
Dear Colleagues,
We are pleased to share the latest progress at EPO in developing tumor resistance models, a key area in preclinical oncology research. Understanding chemoresistance is essential for improving therapeutic strategies, and we continue to lead efforts in this field.
Extensive Chemosensitivity Data
Our broad Patient-Derived Xenograft (PDX) collection covers various tumor types, including solid tumors and leukemias.
With detailed data on chemosensitivity, we can provide models that are either sensitive or resistant to standard-of-care (SoC) drugs, allowing for innovative testing of resistance strategies.
Genomic Insights
We offer integration of chemosensitivity data with RNA sequencing and mutation datasets, available on request. This allows for deeper understanding of drug response and resistance mechanisms to improve research precision.
Induced Resistance Models
EPO has developed select PDX models with induced resistance to drugs like doxorubicin, vincristine, and cetuximab. These models are fully characterized to help identify resistance pathways and new therapeutic approaches.
Highlighting Recent Publications
One notable recent study in the Journal of Controlled Release was co-authored by our team members Dr. Diana Behrens and Prof. Wolfgang Walther. This research demonstrates the efficacy of paclitaxel-loaded polymeric micelles in treating triple-negative breast cancer (TNBC) using our paclitaxel-resistant PDX models.
We also share below recent publications that highlight the value of our PDX models in advancing drug resistance research:
Frontiers in Oncology, 2023: Insights into glioblastoma PDX models and temozolomide resistance.
For more information, contact Turn on Javascript!?subject=Newsletter%20Epo%20GmbH" title="Email-Dr. Dennis Gürgen">Dr. Dennis Gürgen or Turn on Javascript! to discuss how we can accelerate your therapeutic oncology development.
Best regards,
Jens Hoffmann & Wolfgang Walther
CEO & CSO at EPO Berlin-Buch